COMMUNIQUÉS West-GlobeNewswire

Kraig Biocraft Laboratories Positions Itself as a Front-Runner in Spider Silk Race
07/05/2026
Leadership includes Validated Technology, Scalable Production Momentum, and Relentless R&D Execution DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) - In a sector filled with bold claims but [...]
MAPS Welcomes Liana Gillooly and Andrew "Mo" Septimus to Board of Directors
07/05/2026
Liana Sananda Gillooly and Andrew "Mo" Septimus have been elected to the MAPS Board of Directors, bringing complementary expertise across the psychedelic field, ethical business governance, and finance. The appointments [...]
Bruno Vision Care’s Deseyne® Wins 2026 MedTech Breakthrough Award
07/05/2026
Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide LOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- MedTech Breakthrough , an independent market [...]
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
07/05/2026
-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue with the FDA toward [...]
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
07/05/2026
MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its [...]
Stryker declares an $0.88 per share quarterly dividend
07/05/2026
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the [...]
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
07/05/2026
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global regulatory [...]
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
07/05/2026
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic [...]
Willis Knighton Health Selects Commure as Enterprise Ambient Scribe AI Partner
07/05/2026
MOUNTAIN VIEW, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Commure , a leading healthcare technology company, today announced it has been selected by Willis Knighton Health as its enterprise Ambient AI partner. Following a [...]
UroGen Pharma to Present at Upcoming Investor Conferences
07/05/2026
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
07/05/2026
Renewed agreement provides streamlined access to ENvue equipment and supplies across a network of more than 90 hospitals in 17 states TYLER, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc . (NASDAQ: FEED) (“ [...]
MediWound to Report First Quarter 2026 Financial Results
07/05/2026
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global [...]
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
07/05/2026
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant [...]
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
07/05/2026
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental [...]
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
07/05/2026
Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment Financing also drives early- and [...]
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
07/05/2026
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06 [...]
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
07/05/2026
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis [...]
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
07/05/2026
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Phase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, [...]
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
07/05/2026
ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 [...]

Pages